Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria dna vaccine with enhanced protective capabilities

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Luo, Kun ^a   Zhang, Hong ^a   Zavala, Fidel ^a   Biragyn, Arya ^b   Espinosa, Diego A ^a   Markham, Richard B ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MYOD1 PROTEIN; VIMENTIN; CCL20 PROTEIN, HUMAN; DNA VACCINE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MALARIA VACCINE; PARASITE ANTIGEN; PHOSPHATIDYLETHANOLAMINE; PROTOZOON ANTIBODY; VAXFECTIN;

ARTICLE; CDKN2A GENE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC CODE; GENETIC CORRELATION; GENETIC DATABASE; HUMAN; MICROARRAY ANALYSIS; MYOD1 GENE; NONHUMAN; SIGNAL TRANSDUCTION; VIM GENE; ANIMAL; BLOOD; C57BL MOUSE; DENDRITIC CELL; FEMALE; GENETICS; HEK293 CELL LINE; HUMORAL IMMUNITY; IMMUNOLOGY; LIVER; MALARIA; PARASITOLOGY; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; SPOROZOITE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHEMOKINE CCL20; DENDRITIC CELLS; FEMALE; HEK293 CELLS; HUMANS; IMMUNITY, HUMORAL; LIVER; MALARIA; MALARIA VACCINES; MICE, INBRED C57BL; PHOSPHATIDYLETHANOLAMINES; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; RECOMBINANT FUSION PROTEINS; SPOROZOITES; VACCINATION; VACCINES, DNA;

EID: 84897142718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090413     Document Type: Article

References (94)

1. Nussenzweig RS, Vanderberg J, Most H, Orton C (1967) Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 216: 160-162.
2. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, et al. (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 1359-1365.
3. Cockburn IA, Chen YC, Overstreet MG, Lees JR, van Rooijen N, et al. (2010) Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog 6: e1000877.
4. Cockburn IA, Chakravarty S, Overstreet MG, Garcia-Sastre A, Zavala F (2008) Memory CD8+ T cell responses expand when antigen presentation overcomes T cell self-regulation. J Immunol 180: 64-71.
5. Tsuji M, Zavala F (2003) T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol 19: 88-93. (Pubitemid 36173891)
6. Tsuji M, Zavala F (2001) Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites. Mol Immunol 38: 433-442. (Pubitemid 34008473)
7. Carvalho LH, Hafalla JC, Zavala F (2001) ELISPOT assay to measure antigen-specific murine CD8(+) T cell responses. J Immunol Methods 252: 207-218. (Pubitemid 32382105)
8. Nardin E, Zavala F, Nussenzweig V, Nussenzweig RS (1999) Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia 41: 397-402. (Pubitemid 129640285)
9. Rodrigues EG, Zavala F, Nussenzweig RS, Wilson JM, Tsuji M (1998) Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16: 1812-1817. (Pubitemid 28473920)
10. Rodrigues MM, Cordey AS, Arreaza G, Corradin G, Romero P, et al. (1991) CD8 + cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 3: 579-585.
11. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863-1875.
12. Finn JD, Bassett J, Millar JB, Grinshtein N, Yang TC, et al. (2009) Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus. J Virol 83: 12027-12036.
13. Hafalla JC, Morrot A, Sano G, Milon G, Lafaille JJ, et al. (2003) Early self-regulatory mechanisms control the magnitude of CD8+ T cell responses against liver stages of murine malaria. J Immunol 171: 964-970. (Pubitemid 36871411)
14. Hafalla JC, Sano G, Carvalho LH, Morrot A, Zavala F (2002) Short-term antigen presentation and single clonal burst limit the magnitude of the CD8(+) T cell responses to malaria liver stages. Proc Natl Acad Sci U S A 99: 11819-11824. (Pubitemid 34994482)
15. Shin H, Iwasaki A (2012) A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491: 463-467.
16. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
17. Charoenvit Y, Leef MF, Yuan LF, Sedegah M, Beaudoin RL (1987) Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infect Immun 55: 604-608. (Pubitemid 17021948)
18. Charoenvit Y, Mellouk S, Cole C, Bechara R, Leef MF, et al. (1991) Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol 146: 1020-1025.
19. Charoenvit Y, Sedegah M, Yuan LF, Gross M, Cole C, et al. (1990) Active and passive immunization against Plasmodium yoelii sporozoites. Bull World Health Organ 68 Suppl: 26-32.
20. Wang R, Charoenvit Y, Corradin G, Porrozzi R, Hunter RL, et al. (1995) Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol 154: 2784-2793.
21. Doolan DL, Hoffman SL (2001) DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int J Parasitol 31: 753-762. (Pubitemid 32524158)
22. Kumar KA, Sano G, Boscardin S, Nussenzweig RS, Nussenzweig MC, et al. (2006) The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444: 937-940. (Pubitemid 46025007)
23. Weiss WR, Good MF, Hollingdale MR, Miller LH, Berzofsky JA (1989) Genetic control of immunity to Plasmodium yoelii sporozoites. J Immunol 143: 4263-4266. (Pubitemid 20012625)
24. Jaffe RI, Lowell GH, Gordon DM (1990) Differences in susceptibility among mouse strains to infection with Plasmodium berghei (ANKA clone) sporozoites and its relationship to protection by gamma-irradiated sporozoites. Am J Trop Med Hyg 42: 309-313. (Pubitemid 20137301)
25. Scheller LF, Wirtz RA, Azad AF (1994) Susceptibility of different strains of mice to hepatic infection with Plasmodium berghei. Infect Immun 62: 4844-4847. (Pubitemid 24332785)
26. Neimert-Andersson T, Hallgren AC, Andersson M, Langeback J, Zettergren L, et al. (2011) Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccine. Vaccine 29: 8965-8973.
27. Lapteva N, Huang XF (2010) CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther 10: 725-733.
28. Loudon PT, Yager EJ, Lynch DT, Narendran A, Stagnar C, et al. (2010) GMCSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One 5: e11021.
29. Nguyen-Hoai T, Hohn O, Vu MD, Baldenhofer G, Sayed Ahmed MS, et al. (2012) CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC. Cancer Gene Ther 19: 880-887.
30. Zheng Q, Fan D, Gao N, Chen H, Wang J, et al. (2011) Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection. Vaccine 29: 763-771.
31. Rodriguez AM, Pascutti MF, Maeto C, Falivene J, Holgado MP, et al. (2012) IL-12 and GM-CSF in DNA/MVA Immunizations against HIV-1 CRF12-BF Nef Induced T-Cell Responses With an Enhanced Magnitude, Breadth and Quality. PLoS One 7: e37801.
32. Kodama S, Abe N, Hirano T, Suzuki M (2011) A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nontypable Haemophilus influenzae-specific immune responses in the nasal mucosa. Acta Otolaryngol 131: 989-996.
33. Ma X, Li J, Zhang F (2012) Intranasal co-delivery with the mouse zona pellucida 3 and GM-CSF expressing constructs enhances humoral immune responses and contraception in mice. Scand J Immunol 76: 521-527.
34. Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB 2nd, et al. (2012) The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. J Immunother 35: 78-88.
35. Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, et al. (2002) DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 100: 1153-1159. (Pubitemid 34864265)
36. Biragyn A, Ruffini PA, Coscia M, Harvey LK, Neelapu SS, et al. (2004) Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 104: 1961-1969. (Pubitemid 39297844)
37. Biragyn A, Schiavo R, Olkhanud P, Sumitomo K, King A, et al. (2007) Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8 + T cell-mediated protective and therapeutic antitumor immunity. J Immunol 179: 1381-1388.
38. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, et al. (2001) Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 167: 6644-6653. (Pubitemid 33081603)
39. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW (1999) Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17: 253-258. (Pubitemid 29122633)
40. Perales MA, Fantuzzi G, Goldberg SM, Turk MJ, Mortazavi F, et al. (2002) GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines Cell Mol Ther 7: 125-133. (Pubitemid 36850427)
41. Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, et al. (2012) A Vaxfectin-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 30: 7046-7051.
42. Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, et al. (2012) Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immuno-genicity in a murine model of genital herpes infection. J Gen Virol 93: 1305-1315.
43. Sedegah M, Rogers WO, Belmonte A, Belmonte M, Banania G, et al. (2006) Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 24: 1921-1927. (Pubitemid 43238275)
44. Sedegah M, Rogers WO, Belmonte M, Belmonte A, Banania G, et al. (2010) Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine 28: 3055-3065.
45. Luke CJ, Carner K, Liang X, Barbour AG (1997) An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J Infect Dis 175: 91-97. (Pubitemid 27020829)
46. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, et al. (1983) Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301: 214-221. (Pubitemid 13142222)
47. Hartikka J, Bozoukova V, Ferrari M, Sukhu L, Enas J, et al. (2001) Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19: 1911-1923. (Pubitemid 32178339)
48. Persson C, Oliveira GA, Sultan AA, Bhanot P, Nussenzweig V, et al. (2002) Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 169: 6681-6685. (Pubitemid 36899251)
49. Del Giudice G, Lambert PH, Mendis K, Pessi A, Tanner M (1990) Antibody responses to Plasmodium falciparum and P. vivax sporozoites in areas with stable and unstable malaria. Bull World Health Organ 68 Suppl: 191-196.
50. Noland GS, Chowdhury DR, Urban JF Jr, Zavala F, Kumar N (2010) Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice. Vaccine 28: 2917-2923.
51. Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, et al. (1982) Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 156: 20-30. (Pubitemid 12082484)
52. Zavala F, Tam JP, Hollingdale MR, Cochrane AH, Quakyi I, et al. (1985) Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228: 1436-1440. (Pubitemid 15041321)
53. Witney AA, Doolan DL, Anthony RM, Weiss WR, Hoffman SL, et al. (2001) Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. Mol Biochem Parasitol 118: 233-245. (Pubitemid 34001686)
54. Shlapobersky M, Wei Q, Sullivan S, Vilalta A (2009) Vaxfectin-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters. Vaccine 27: 6404-6410.
55. Hedstrom RC, Doolan DL, Wang R, Kumar A, Sacci JB Jr, et al. (1998) In vitro expression and in vivo immunogenicity of Plasmodium falciparum preerythrocytic stage DNA vaccines. Int J Mol Med 2: 29-38.
56. Sano G, Hafalla JC, Morrot A, Abe R, Lafaille JJ, et al. (2001) Swift development of protective effector functions in naive CD8(+) T cells against malaria liver stages. J Exp Med 194: 173-180.
57. Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M (1997) Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol 158: 1268-1274. (Pubitemid 127469951)
58. Zavala F (1991) The multifactorial character of the protective immunity induced by immunization with sporozoites. Res Immunol 142: 654-658.
59. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, et al. (1989) Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341: 323-326. (Pubitemid 20102099)
60. Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, et al. (2008) Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A 105: 14017-14022.
61. Amante FH, Good MF (1997) Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunol 19: 111-126. (Pubitemid 27138285)
62. Wang R, Charoenvit Y, Corradin G, De La Vega P, Franke ED, et al. (1996) Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4 + T cell- and IFN-gamma-dependent elimination of infected hepatocytes. J Immunol 157: 4061-4067. (Pubitemid 126449317)
63. Renia L, Grillot D, Marussig M, Corradin G, Miltgen F, et al. (1993) Effector functions of circumsporozoite peptide-primed CD4+ T cell clones against Plasmodium yoelii liver stages. J Immunol 150: 1471-1478. (Pubitemid 23127437)
64. Ambrosini E, Remoli ME, Giacomini E, Rosicarelli B, Serafini B, et al. (2005) Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol 64: 706-715. (Pubitemid 41179012)
65. Cremel M, Berlier W, Hamzeh H, Cognasse F, Lawrence P, et al. (2005) Characterization of CCL20 secretion by human epithelial vaginal cells: involvement in Langerhans cell precursor attraction. J Leukoc Biol 78: 158-166. (Pubitemid 40979954)
66. Zhao X, Jain S, Benjamin Larman H, Gonzalez S, Irvine DJ (2005) Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials 26: 5048-5063. (Pubitemid 40354238)
67. Wu YY, Tsai HF, Lin WC, Hsu PI, Shun CT, et al. (2007) Upregulation of CCL20 and recruitment of CCR6+ gastric infiltrating lymphocytes in Helicobacter pylori gastritis. Infect Immun 75: 4357-4363.
68. He S, Cao Q, Yoneyama H, Ge H, Zhang Y, et al. (2008) MIP-3alpha and MIP-1alpha rapidly mobilize dendritic cell precursors into the peripheral blood. J Leukoc Biol 84: 1549-1556. (Pubitemid 352774490)
69. Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, et al. (2008) CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 181: 8391-8401.
70. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, et al. (2009) CC chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10: 514-523.
71. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, et al. (2010) Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97-106.
72. Hafalla JC, Rai U, Morrot A, Bernal-Rubio D, Zavala F, et al. (2006) Priming of CD8+ T cell responses following immunization with heat-killed Plasmodium sporozoites. Eur J Immunol 36: 1179-1186.
73. Mueller AK, Labaied M, Kappe SH, Matuschewski K (2005) Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433: 164-167.
74. Sun P, Schwenk R, White K, Stoute JA, Cohen J, et al. (2003) Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 171: 6961-6967. (Pubitemid 37532133)
75. Sedegah M, Belmonte M, Epstein JE, Siegrist CA, Weiss WR, et al. (2003) Successful induction of CD8 T cell-dependent protection against malaria by sequential immunization with DNA and recombinant poxvirus of neonatal mice born to immune mothers. J Immunol 171: 3148-3153. (Pubitemid 37093539)
76. Luke TC, Hoffman SL (2003) Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 206: 3803-3808. (Pubitemid 37365462)
77. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, et al. (2002) Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155-1164. (Pubitemid 34297774)
78. Vichier-Guerre S, Lo-Man R, BenMohamed L, Deriaud E, Kovats S, et al. (2003) Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use. J Pept Res 62: 117-124. (Pubitemid 36995122)
79. Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, et al. (2004) Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 172: 2487-2495. (Pubitemid 38182399)
80. Doolan DL, Hoffman SL (2000) The complexity of protective immunity against liver-stage malaria. J Immunol 165: 1453-1462. (Pubitemid 30604578)
81. Bonelo A, Valmori D, Triponez F, Tiercy JM, Mentha G, et al. (2000) Generation and characterization of malaria-specific human CD8(+) lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentationby liver cells. Eur J Immunol 30: 3079-3088.
82. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, et al. (2003) Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14: 709-714. (Pubitemid 36623509)
83. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, et al. (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22: 2489-2493. (Pubitemid 38757348)
84. Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, et al. (2007) Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81: 5257-5269. (Pubitemid 46744435)
85. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, et al. (2008) Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26: 440-448.
86. Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, et al. (2009) DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A 106: 15831-15836.
87. Patel V, Valentin A, Kulkarni V, Rosati M, Bergamaschi C, et al. (2010) Longlasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 28: 4827-4836.
88. Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, et al. (2011) Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 203: 95-102.
89. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, et al. (2010) Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28: 2565-2572.
90. Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, et al. (2002) Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 13: 1551-1560. (Pubitemid 35034675)
91. Limbach K, Aguiar J, Gowda K, Patterson N, Abot E, et al. (2011) Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates. Malar J 10: 65.
92. Scheiblhofer S, Chen D, Weiss R, Khan F, Mostbock S, et al. (2001) Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improvesprotection against malaria infection. Eur J Immunol 31: 692-698. (Pubitemid 32237104)
93. Vanderberg J, Mueller AK, Heiss K, Goetz K, Matuschewski K, et al. (2007) Assessment of antibody protection against malaria sporozoites must be done by mosquito injection of sporozoites. Am J Pathol 171: 1405-1406; author reply 1406.
94. Vanderberg JP, Frevert U (2004) Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol 34: 991-996. (Pubitemid 39093800)